Atara Biotherapeutics Inc represents values such as innovation, scientific excellence, and patient-centricity. With a focus on developing transformative therapies for patients with serious medical conditions, Atara Biotherapeutics Inc aims to improve and extend lives. The company's corporate philosophy revolves around collaboration, dedication to research and development, and a commitment to delivering safe and effective treatments. Atara Biotherapeutics Inc continuously strives to address unmet medical needs and make a positive impact in the field of biopharmaceuticals, utilizing cutting-edge technologies and expertise to bring potential breakthroughs to patients in need.

Atara Biotherapeutics Inc is primarily present in the United States.

Atara Biotherapeutics Inc has achieved significant milestones since its establishment. Some notable achievements include the successful development and clinical progress of its innovative therapies for patients with serious diseases. The company has also made remarkable advancements in its pipeline, with the approval of certain products by regulatory authorities. Moreover, Atara Biotherapeutics Inc has entered into strategic collaborations and partnerships, strengthening its position in the biopharmaceutical industry. These achievements demonstrate the company's dedication to making breakthrough discoveries and providing effective treatments for patients in need. Atara Biotherapeutics Inc continues to strive for further milestones and growth in its pursuit of improving healthcare outcomes.

Atara Biotherapeutics Inc is a biotechnology company specializing in developing novel therapies for patients with serious medical conditions. Established in 2012, the company is headquartered in South San Francisco, California. Atara Biotherapeutics Inc focuses on developing off-the-shelf T-cell immunotherapies with the potential to target multiple diseases. By harnessing the power of the immune system, the company aims to provide innovative treatment options for cancer and autoimmune diseases. Atara's robust portfolio includes both clinical and preclinical stage therapies, which are designed to address the unmet medical needs of patients worldwide. With a dedicated team of scientists and researchers, Atara Biotherapeutics Inc continues to advance its mission of transforming medical care through groundbreaking biotechnology.

The main competitors of Atara Biotherapeutics Inc in the market are companies such as Novartis International AG, Gilead Sciences Inc, and Kite Pharma Inc.

Atara Biotherapeutics Inc is primarily active in the biotechnology industry.

Atara Biotherapeutics Inc. operates under a business model focused on developing and commercializing transformative therapies for patients with serious medical conditions. With a strong emphasis on targeted immunotherapies, the company utilizes its proprietary cell therapy platforms to create innovative treatments that harness the immune system's ability to fight diseases. Atara Biotherapeutics aims to address the unmet medical needs of patients through the development of novel therapies that target specific antigens associated with various diseases, including cancer, autoimmune disorders, and viral infections. By leveraging advanced scientific technologies, Atara Biotherapeutics Inc. strives to improve patient outcomes and quality of life.

P/E-forholdet til Atara Biotherapeutics er −0,36.

Atara Biotherapeutics KUV er 0,27.

AlleAktien kvalitetsscore for Atara Biotherapeutics er 5/10.

forventede Atara Biotherapeutics omsetningen er 112,10 mill. USD.

forventede Atara Biotherapeutics -gevinsten er −84,65 mill. USD.

Atara Biotherapeutics Inc is a US biotechnology company specializing in the development of immunotherapies for rare diseases. The company was founded in 2012 and is headquartered in South San Francisco, California. Atara Biotherapeutics' business model is focused on the development and commercialization of immunotherapies for rare diseases. The company has focused on two main areas: cancer and virus-related immune disorders. In the field of cancer, Atara Biotherapeutics has developed several immuno-oncology therapies aimed at stimulating the body's immune system to attack and destroy tumor cells. An example is Tabelecleucel (tab-cel®), an immunotherapy used to treat EBV-associated post-transplant lymphoproliferative disorder (PTLD) and EBV-associated hemophagocytic lymphohistiocytosis (HLH). The company is also working on CAR-T cell therapies for cancer treatment. In the field of virus-related immune disorders, Atara Biotherapeutics has developed therapies for diseases such as cytomegalovirus (CMV). The company has also developed an immunotherapy called Pooled Normal Human Immunoglobulin (IVIG), used to treat primary immune deficiency disorder (PIDD), a rare immune system disorder. The company is also working on the development of therapies for the treatment of COVID-19. Atara Biotherapeutics pursues an extensive research and development program focused on discovering new therapies for rare diseases. The company collaborates with leading experts in the field of immunotherapy to develop innovative new approaches to disease treatment. The company has also formed partnerships with leading pharmaceutical and biotech companies to accelerate its research and development programs and bring its products to new markets. Atara Biotherapeutics also works closely with patient organizations and regulatory agencies to better understand the needs and desires of patients and ensure that all products meet the highest safety and quality standards. Overall, Atara Biotherapeutics' business model aims to develop and commercialize new therapies for rare diseases that have not been adequately treated in the past. The company relies on close collaboration with leading experts, patient organizations, regulatory agencies, and other companies to develop innovative new approaches to disease treatment and establish worldwide leadership positions.

Atara Biotherapeutics utbetaler et dividende på 0 USD fordelt over utdelinger i året.

Utbyttet kan for øyeblikket ikke beregnes for Atara Biotherapeutics eller så utdeler ikke selskapet utbytte.

ISIN-en til Atara Biotherapeutics er US0465131078.

WKN for Atara Biotherapeutics er A1166A.

Tikkeren til Atara Biotherapeutics er ATRA.

I løpet av de siste 12 månedene utbetalte Atara Biotherapeutics et utbytte på . Dette tilsvarer en utbytteavkastning på ca. . For de neste 12 månedene vil Atara Biotherapeutics sannsynligvis betale et utbytte på 0 USD.

Utdelingsrendementet til Atara Biotherapeutics er for øyeblikket .

Atara Biotherapeutics betaler utbytte kvartalsvis. Dette blir utdelt i månedene .

Atara Biotherapeutics betalte utbytte hvert år de siste 0 årene.

For de kommende 12 månedene forventes det utbytter på 0 USD. Dette tilsvarer en utbytteavkastning på 0 %.

Atara Biotherapeutics tilordnes sektoren 'Helse'.

For å motta den siste utbyttet fra Atara Biotherapeutics den på 0 USD, måtte du ha aksjen i porteføljen din før ex-datoen den .

Utbetalingen av det siste utbyttet fant sted den .

I løpet av 2023 ble det utbetalt 0 USD i utbytte fra Atara Biotherapeutics.

Utdelingene fra Atara Biotherapeutics blir betalt ut i USD.